LeJeune Puetz Investment Counsel’s Biohaven Pharmaceutical Holding Company Ltd. BHVN Stock Holding History

LeJeune Puetz Investment Counsel’s Portfolio BHVN Stock Details BHVN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-3,950	Closed	-$544K	–	200
2021 Q4	$544K	Hold	3,950	–	–	0.18%	111
2021 Q3	$549K	Sell	3,950 -1,300	-25%	-$162K	0.2%	108
2021 Q2	$510K	Sell	5,250 -2,000	-28%	-$162K	0.19%	110
2021 Q1	$496K	Buy	7,250 +1,400	+24%	+$113K	0.19%	108
2020 Q4	$501K	Hold	5,850	–	–	0.22%	105
2020 Q3	$380K	Sell	5,850 -7,900	-57%	-$518K	0.19%	110
2020 Q2	$174K	Buy	+13,750	New	+$732K	0.09%	143

Other funds holding BHVN

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Stifel Financial St. Louis, Missouri $120B AUM 27.84% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Allspring Global Investments Charlotte, North Carolina $59.7B AUM 29.08% 1-Year Est. Return

OIM

Oracle Investment Management Greenwich, Connecticut $168M AUM 42.86% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

LeJeune Puetz Investment Counsel's BHVN Position: Q1 2022 in Review

LeJeune Puetz Investment Counsel sold out of Biohaven Pharmaceutical Holding Company Ltd. (BHVN) in Q1 2022, closing a stake of 3,950 shares — an estimated $544K sold.

LeJeune Puetz Investment Counsel first reported a position in BHVN in Q2 2020 and held it in 7 quarters. The position peaked at $549K in Q3 2021. 307 funds tracked by Wall St. Rank hold BHVN as of Q1 2022.

LeJeune Puetz Investment Counsel reported no remaining Biohaven Pharmaceutical Holding Company Ltd. position as of Q1 2022 after selling out during the quarter.
LeJeune Puetz Investment Counsel sold 3,950 Biohaven Pharmaceutical Holding Company Ltd. shares in Q1 2022, an estimated $544K.
LeJeune Puetz Investment Counsel first reported a position in Biohaven Pharmaceutical Holding Company Ltd. in Q2 2020 and held it in 7 quarters.
LeJeune Puetz Investment Counsel's Biohaven Pharmaceutical Holding Company Ltd. position peaked at $549K in Q3 2021.
307 funds tracked by Wall St. Rank held Biohaven Pharmaceutical Holding Company Ltd. as of Q1 2022.

Based on LeJeune Puetz Investment Counsel's 13F filing for Q1 2022, filed 2 May 2022.